Demographic characterization of Brazilian patients enrolled in the Fabry Registry

被引:9
|
作者
Martins, A. M. [1 ]
Kyosen, S. O. [1 ]
Garrote, J. [1 ]
Marques, F. M. V. [2 ]
Guilhem, J. G. [3 ]
Macedo, E. [4 ]
Sobral Neto, J. [5 ]
Ura, S. [6 ]
机构
[1] Univ Fed Sao Paulo, Dept Pediat, Ctr Referencia Erros Inatos Metab, Sao Paulo, Brazil
[2] Hosp Santo Antonio, Tapejara, RS, Brazil
[3] Inst Hemodialise Sorocaba, Sorocaba, SP, Brazil
[4] Ctr Infusao Doencas Raras, Curimata, PI, Brazil
[5] Ctr Avaliacao Cardiol, Ctr Card, Brasilia, DF, Brazil
[6] Inst Lauro de Souza Lima, Bauru, SP, Brazil
关键词
Fabry disease; Alpha-galactosidase A deficiency; Fabry Registry; Brazil; Demographics; DISEASE; FEMALES;
D O I
10.4238/2013.January.24.5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fabry disease (FD) is an X-linked inborn error of metabolism caused by alpha-galactosidase A deficiency. The Fabry Registry is an ongoing observational database that compiles clinical data on patients with FD. We analyzed the Fabry Registry data of patients enrolled in Brazil to characterize the demographic and baseline clinical characteristics of this patient population. As of October 2010, 126 Brazilian patients were enrolled in the Registry (61 males, 65 females). The median age at onset of symptoms in males was 9.8 years, compared to 11.4 years in females. Males were diagnosed at a median age of 31.9 years and females at 27.1 years. The median time between the onset of first symptoms and diagnosis was 20.3 years in males and 14.3 years in females. Neurologic pain was the presenting symptom most frequently reported by both genders. Renal events were the most common clinical events reported in males, while cardiac events were the most common events in females. The results of these analyses indicate that Brazilian patients were frequently not diagnosed with FD until many years after the onset of symptoms. Many Brazilian Fabry Registry patients report experiencing neurological pain, and many Brazilian women with FD exhibit substantial signs and symptoms. The prevalence of neurological pain as a presenting symptom among Brazilian Registry patients is consistent with previous reports from the overall Registry population. FD is treatable, and earlier diagnosis will allow for prompt initiation of appropriate treatment that may avert irreversible damage that could occur during the time from symptom onset to diagnosis.
引用
收藏
页码:136 / 142
页数:7
相关论文
共 50 条
  • [1] Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry
    Politei, J. M.
    Cabrera, G.
    Amartino, H.
    Valdez, R.
    Masllorens, F.
    Ripeau, D.
    Antongiovanni, N.
    Soliani, A.
    Luna, P.
    Cedrolla, M.
    Fernandez, S.
    Fainboim, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (01) : 66 - 72
  • [2] Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative
    Sirrs, S.
    Clarke, J. T. R.
    Bichet, D. G.
    Casey, R.
    Lemoine, K.
    Flowerdew, G.
    Sinasac, D. S.
    West, M. L.
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (04) : 367 - 373
  • [3] The Fabry Registry: Looking at Tomorrow
    Sims, Katherine B.
    CLINICAL THERAPEUTICS, 2009, 31 : S22 - S23
  • [4] Comparison of patients from a Spanish Registry of Fabry disease in two periods
    Barba Romero, Miguel Angel
    Rivera Gallego, Alberto
    Pintos Morell, Guillem
    MEDICINA CLINICA, 2012, 139 (09): : 379 - 384
  • [5] Genomic analysis of Brazilian patients with Fabry disease
    Pereira, F. S.
    Jardim, L. B.
    Netto, C. B.
    Burin, M. G.
    Cecchin, C.
    Giugliani, R.
    Matte, U. S.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2007, 40 (12) : 1599 - 1604
  • [6] End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
    Ortiz, Alberto
    Cianciaruso, Bruno
    Cizmarik, Marta
    Germain, Dominique P.
    Mignani, Renzo
    Oliveira, Joao Paulo
    Villalobos, Jacobo
    Vujkovac, Bojan
    Waldek, Stephen
    Wanner, Christoph
    Warnock, David G.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (03) : 769 - 775
  • [7] Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
    Watt, Torquil
    Burlina, Alessandro P.
    Cazzorla, Chiara
    Schoenfeld, Dorothee
    Banikazemi, Maryam
    Hopkin, Robert J.
    Martins, Ana Maria
    Sims, Katherine
    Beitner-Johnson, Dana
    O'Brien, Fanny
    Feldt-Rasmussen, Ulla
    GENETICS IN MEDICINE, 2010, 12 (11) : 703 - 712
  • [8] Characterization of vertigo and hearing loss in patients with Fabry disease
    Koeping, Maria
    Shehata-Dieler, Wafaa
    Schneider, Dieter
    Cebulla, Mario
    Oder, Daniel
    Muentze, Jonas
    Nordbeck, Peter
    Wanner, Christoph
    Hagen, Rudolf
    Schraven, Sebastian P.
    ORPHANET JOURNAL OF RARE DISEASES, 2018, 13
  • [9] Cardiovascular Events in Patients With Fabry Disease Natural History Data From the Fabry Registry
    Patel, Manesh R.
    Cecchi, Franco
    Cizmarik, Marta
    Kantola, Ilkka
    Linhart, Ales
    Nicholls, Kathy
    Strotmann, Joerg
    Tallaj, Jose
    Thi Chien Tran
    West, Michael L.
    Beitner-Johnson, Dana
    Abiose, Ademola
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (09) : 1093 - 1099
  • [10] Fabry's Disease: New concepts in its natural history, evolution and treatment, in relation to the findings in the Fabry's Registry
    Politei, Juan Manuel
    Cabello, Juan Francisco
    Villalobos, Jacobo
    Valadez, Guillermo
    Loaeza, Antonio
    Linares, Adriana
    Martins, Ana Maria
    REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2009, 29 (04): : 145 - 152